Each week, we identify one top search term, speculate as to what caused its popularity, and provide an infographic on a related condition. If you have thoughts about what's trending and why, feel free to share them with us on Twitter or Facebook!
Clinical Trend of the Week (July 22-28): Vitiligo
A potentially promising treatment for a fairly common condition is responsible for this week’s top search term. Vitiligo, which has a prevalence rate of 1%-2%, is notoriously difficult to treat. This is why the potential use of Janus kinase (JAK) inhibitors represents an exciting development. A recent proof-of-concept study found that twice-daily topical ruxolitinib 1.5% cream was associated with a 23% overall improvement in Vitiligo Area Scoring Index (VASI) totals. The scores were most improved for facial vitiligo, and side effects were mild. The next step is randomized, placebo controlled clinical trials that will help quantify the efficacy and clarify the safety. Further news is no doubt eagerly awaited by patients with vitiligo and those that treat them.
For more information on vitiligo, read here.
Medscape © 2017
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Ryan Syrek. Clinical Trends for July 2017 - Medscape - Jul 28, 2017.